AveXis Announces Dosing of First Patient for Gene Transfer Clinical Trial for …

AveXis Announces Dosing of First Patient for Gene Transfer Clinical Trial for …

In preclinical studies, AAV9 has been shown to cross the bloodbrainbarrier, delivering SMN to motor neurons and significantly improve survival and motor function in an animal model of SMA. “Over the past few months so many individuals, organizations

(Visited 2 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.